Literature DB >> 24206371

In-patient discharge rates for the irritable bowel syndrome - an analysis of national trends in the United States from 1997 to 2010.

S Sethi1, V Wadhwa, J LeClair, S Mikami, R Park, M Jones, N Sethi, A Brown, A Lembo.   

Abstract

BACKGROUND: Irritable bowel syndrome (IBS) is one of the most common out-patient diagnoses in primary care and gastroenterology. There are limited data on the rate and costs associated with in-patient discharges for IBS. AIM: To estimate the incidence and costs of hospital discharges for IBS in the United States.
METHODS: We analysed the National Inpatient Sample database for all subjects in which IBS (ICD-9 code: 564.1) was the principal discharge diagnosis from 1997 to 2010. The National Inpatient Sample contains data from approximately 8 million hospital stays each year. Our findings reflected patient and hospital characteristics like geographical region and bed size.
RESULTS: In 1997, there were 11 433 patients with a principal discharge diagnosis of IBS as compared to 12 842 in 2010 (P > 0.9, GoF test). The mean length of stay for IBS also remained the same between 1997 and 2010 at 3.7 ± 0.1 days. However, during this period, the mean hospital charges per hospitalization increased by 207.8% from $6873 ± 198 in 1997 to $21 153 ± 598 in 2010 (P < 0.01). The aggregate charges (i.e., 'national bill') for IBS increased by 245.5% from $78 524 129 ± 3 781 316 in 1997 to $271 311 405 ± 14 023 289 in 2010 (P < 0.01).
CONCLUSIONS: The number of in-patient discharges and length of stay for IBS have remained relatively stable between 1997 and 2010, whereas the cost associated with these discharges has increased significantly. In-patient costs associated with IBS contribute significantly to the total healthcare bill. Further research on the cost-effectiveness of diagnostic procedures and therapies in IBS is required.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24206371     DOI: 10.1111/apt.12532

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

2.  Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults.

Authors:  Ammar Hassanzadeh Keshteli; Babak Dehestani; Hamed Daghaghzadeh; Peyman Adibi
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

3.  Changing Trends in Age, Gender, Racial Distribution and Inpatient Burden of Achalasia.

Authors:  Vaibhav Wadhwa; Prashanthi N Thota; Malav P Parikh; Rocio Lopez; Madhusudhan R Sanaka
Journal:  Gastroenterology Res       Date:  2017-04-19

4.  Healthcare utilization and costs associated with gastroparesis.

Authors:  Vaibhav Wadhwa; Dhruv Mehta; Yash Jobanputra; Rocio Lopez; Prashanthi N Thota; Madhusudhan R Sanaka
Journal:  World J Gastroenterol       Date:  2017-06-28       Impact factor: 5.742

5.  Nationwide trends of hospital admissions for acute cholecystitis in the United States.

Authors:  Vaibhav Wadhwa; Yash Jobanputra; Sushil K Garg; Soumil Patwardhan; Dhruv Mehta; Madhusudhan R Sanaka
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-05-11

6.  Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.

Authors:  Jan Tack; Vincenzo Stanghellini; Fermín Mearin; Yan Yiannakou; Peter Layer; Benoit Coffin; Magnus Simren; Jonathan Mackinnon; Gwen Wiseman; Anne Marciniak
Journal:  BMC Gastroenterol       Date:  2019-05-07       Impact factor: 3.067

Review 7.  Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome.

Authors:  Brian E Lacy
Journal:  Aliment Pharmacol Ther       Date:  2018-09-07       Impact factor: 8.171

8.  Healthcare utilization and costs associated with cholangiocarcinoma.

Authors:  Vaibhav Wadhwa; Yash Jobanputra; Prashanthi N Thota; K V Narayanan Menon; Mansour A Parsi; Madhusudhan R Sanaka
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.